**Section: Contact Information**

First Name: Christopher  
Last Name: Weldon  
Institution: Boston Children's Hospital / DFCI  
Address 1: 300 Longwood Ave  
Address 2: Fegan 3rd Floor  
City: Boston  
State/Province/Region: MA  
Country: US  
Zip/Postal Code: 02115  
Phone Number: (617) 355-7800  
Alternate Phone Number:  
Email Address: christopher.weldon@childrens.harvard.edu

**Section: Project Requirements and Description**

**Group: Requirements to submit AOI**

A comprehensive review of previously published data has been completed. : Yes  
The specific aims are clear and focused. : Yes  
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator. : Yes  
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months. : Yes  
Project Title: Long-Term Outcomes among Survivors of Childhood Ewing Sarcoma  
Planned research population (eligibility criteria):  
All 5-year survivors (baseline and expanded cohorts) diagnosed with Ewing sarcoma at age <21.  
Proposed specific aims:  
S.A. 1: To describe the patterns over time of the cumulative incidence of late complications (including mortality [primary], second neoplasm [secondary], and CTCAE chronic health conditions [secondary]) among survivors of Ewing sarcoma (and sibling controls).  
S.A. 2: To describe the patterns over time of the multimodal strategies (surgery, chemotherapy, radiotherapy) used in the treatment of Ewing sarcoma.  
S.A. 3: To identify risk factors for the above primary (i.e. mortality) and secondary outcomes (including second neoplasm and chronic health conditions).  
Will the project require non-CCSS funding to complete? : No  
If yes, what would be the anticipated source(s) and timeline(s) for securing funding? : N/A

**Group: Does this project require contact of CCSS study subjects for:**

Additional self-reported information : No
Biological samples: No
Medical record data: No
If yes to any of the above, please briefly describe:

**Group: What CCSS Working Group(s) would likely be involved? (Check all that apply)**
- Second Malignancy: Secondary
- Chronic Disease: Primary
- Psychology / Neuropsychology:
- Genetics:
- Cancer Control:
- Epidemiology / Biostatistics: Secondary

**Section: Outcomes or Correlative Factors**
- Late mortality: Primary
- Second Malignancy: Secondary

**Group: Health Behaviors**
- Tobacco: Correlative Factors
- Alcohol:
- Physical activity: Secondary, Correlative Factors
- Medical screening: Secondary
- Other:
  If other, please specify:

**Group: Psychosocial**
- Insurance:
- Marriage:
- Education:
- Employment:
- Other:
  If other, please specify:

**Group: Medical Conditions**
- Hearing/Vision/Speech:
- Hormonal systems:
- Heart and vascular: Secondary
- Respiratory: Secondary
- Digestive: Secondary
- Surgical procedures: Secondary, Correlative Factors
- Brain and nervous system: Secondary, Correlative Factors
- Other: Correlative Factors
  If other, please specify:
**Group: Medications**
Describe medications:

**Group: Psychologic/Quality of Life**
BSI-18:
SF-36:
CCSS-NCQ:
PTS:
PTG:
Other:
If other, please specify:

**Group: Other**
Pregnancy and offspring: **Secondary**
Family history:
Chronic conditions (CTCAE v3): **Secondary**
Health status: **Secondary**

**Group: Demographic**
Age: **Correlative Factors**
Race: **Correlative Factors**
Sex: **Correlative Factors**
Other:
If other, please specify:

**Group: Cancer treatment**
Chemotherapy: **Correlative Factors**
Radiation therapy: **Correlative Factors**
Surgery: **Correlative Factors**

**Section: Anticipated Sources of Statistical Support**
CCSS Statistical Center: **Yes**
Local institutional statistician:
If local, please provide the name(s) and contact information of the statistician(s) to be involved.
Will this project utilize CCSS biologic samples?: **No**
If yes, which of the following?:
If other, please explain:

**Section: Other General Comments**
Other General Comments:
This analysis will include surgical data from the expansion cohort.